MedTrace Logo

Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D

NCT00977080 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 272

Last updated 2012-06-20

Study results available
· View outcomes & findings →

Summary

Evaluates the effectiveness of on-label Paricalcitol versus Cinacalcet with Low-Dose Vitamin D.

Conditions

Interventions

DRUG

Paricalcitol

Paricalcitol dosed per label by region (participants were to receive cinacalcet if they developed hypercalcemia)

DRUG

Cinacalcet

On-label oral cinacalcet by region with low dose vitamin D receptor activator (VDRA) (either doxercalciferol at US sites or alfacalcidol at non-US sites)

Sponsors & Collaborators

Principal Investigators

  • Samina Khan, MD · Abbott

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2011-05-31
Completion
2011-05-31

Countries

  • United States
  • Czechia
  • Denmark
  • Germany
  • Greece
  • Italy
  • Netherlands
  • Portugal
  • Russia
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00977080 on ClinicalTrials.gov